SELECTIVE TARGETING OF FCRN AND IGG CLEARANCE BY NIPOCALIMAB PRESERVES KEY IMMUNE FUNCTIONS LE Ling; S Tyler; CJ Beneduce; F Yu; J Brown; S Kumar; R Xu; J Duffner; AB Perdomo; W Avery;

A PHASE 1 PLACEBO-CONTROLLED SINGLE-DOSE STUDY OF NIPOCALIMAB ADMINISTERED AT DIFFERENT RATES OF INTRAVENOUS INFUSION IN HEALTHY ADULTS JH Leu; A Vermeulen; AB Perdomo; LE Ling;